AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan

MLA

Jonathan Rubino, et al. “AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and Irinotecan.” Journal of Clinical Oncology, vol. 37, May 2019, p. 10047. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4655d1326960f9c44fe9d99d10c3c7bb&authtype=sso&custid=ns315887.

APA

Jonathan Rubino, Gilles Vassal, Windy Rondof, Nicolas André, Caroline Rossoni, Xavier Paoletti, Souad Nebchi, Daniel Hübschmann, Peter G. Mortimer, Estelle Thebaud, Birgit Geoerger, Isabelle Aerts, & Susanne A. Gatz. (2019). AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan. Journal of Clinical Oncology, 37, 10047.

Chicago

Jonathan Rubino, Gilles Vassal, Windy Rondof, Nicolas André, Caroline Rossoni, Xavier Paoletti, Souad Nebchi, et al. 2019. “AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and Irinotecan.” Journal of Clinical Oncology 37 (May): 10047. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4655d1326960f9c44fe9d99d10c3c7bb&authtype=sso&custid=ns315887.